Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Syed Aga"'
Autor:
Mubarak Al-Mansour, Saif Ahmed Saif, Ziyad Alharbi, Abdulrhman Salem Alhwaity, Ahmed Almasrahi, Waleed Alnejadi, Sarah Hussain, Syed Aga, Muhammad Khan, Roula Almufti, Ahmed Absi
Publikováno v:
Asian Pacific Journal of Cancer Prevention. 24:623-631
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4496a162cc2a776c63b0ff91878333f3
https://doi.org/10.31557/apjcp.2023.24.2.623
https://doi.org/10.31557/apjcp.2023.24.2.623
Autor:
Mohammad J Khalifah, Omar Almansouri, Abdulfattah Mowallad, Syed Aga, Ammar A Aljefri, Abdulaziz Almalki, Naser Alhmdan, Wael Al-Mazain, Khalid Alsalmi
Publikováno v:
Cureus. 14(11)
The detection of autoantibodies directed toward nuclear antigens is one of the main criteria for the diagnosis of systemic lupus erythematosus (SLE), for which the most commonly used techniques are the enzyme immunoassay and immunofluorescence assay
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb5d9274bf9fc09a7d4c01e358894e2c
https://pubmed.ncbi.nlm.nih.gov/36475172
https://pubmed.ncbi.nlm.nih.gov/36475172
Autor:
Mubarak Al‑Μansour, Ahmed Absi, Roula Al‑Μufti, Majed Alahmadi, Ihab El‑Ηemaidi, Sameer Alamoudi, Saleem Eldadah, Syed Aga, Muhammed Khan, Ahmed Alsaeed
Publikováno v:
Molecular and clinical oncology. 17(6)
Central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) is rare (2-5% of cases), but is a devastating complication with a poor survival rate. The administration of high-dose methotrexate (HDMTX) for CNS prophylaxis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c373059579da680f3cf82995570e9d3
https://pubmed.ncbi.nlm.nih.gov/36338604
https://pubmed.ncbi.nlm.nih.gov/36338604
Autor:
Meteb Al‑Foheidi, Asem Albeshri, Safwan Moamenkahan, Abdulmajid Abdullah, Muhannad Abualola, Muath Alharbi, Ahmed Refa, Ali Bayer, Ahmed Shaheen, Syed Aga, Muhammad Khan, Mubarak Al‑Mansour, Ezzeldin Ibrahim
Publikováno v:
Molecular and clinical oncology. 17(1)
The addition of palbociclib (a cyclin-dependent kinase 4/6 inhibitor) to endocrine therapy (ET) has been shown to significantly improve progression-free survival (PFS) and overall survival (OS) among patients with hormone receptor-positive (HR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed0d1d435f1071aaaca12031ed1c2d33
https://pubmed.ncbi.nlm.nih.gov/35747598
https://pubmed.ncbi.nlm.nih.gov/35747598
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.